Board of Directors

 

Johan Reinsli 

Chairman of the Board. Johan Reinsli was elected Chairmain of the Board in March 2008. He has been a board member in Navamedic since March 2007. Mr Reinsli is a graduate from Handelsakademiet, Oslo, Norway and has broad international management experience from the banking and finance sector. Previous executives positiones includes EVP at DnB NOR Kort, Head of Northern Europe at Europay International SA and CEO at Europrocessing International ASA, a company founded by Mr. Reinsli and colleagues. During his career Mr. Reinsli has been completing M&A activities in a number of EU and neighbouring countries.  Mr Reinsli has broad international back ground from various Board assignements, and currently works as an independent advisor and board member. Johan Reinsli's term expires at the annual general meeting in 2012. Mr Reinsli holds indirectly 222,200 shares in the Company. 

Benedicte Heidenreich FossumBenedicte Heidenreich Fossum

was elected a Director of Navamedic in March 2005. Ms Fossum is a graduate from the Norwegian School of Veterinary Science from which she holds a degree in Veterinarian medicine. She is Senior Director of Market Development and Member of the Board in Pharmaq AS. Her previous experience is from among others Alpharma (Regulatory Manager) and the Norwegian Medicines Agency (Statens Legemiddelverk). Benedicte Fossum’s term expires at the annual general meeting in 2012. Mrs Fossum holds indirectly 30,000 shares in the Company.

Halvor StenstadvoldHalvor Stenstadvold

was elected Director of Navamedic in March 2008. Mr Stenstadvold holds a MSc Political Science from the University of Oslo. Mr Stenstadvold has long experience from different positions in Orkla, i.e responsible for Orkla Group's staff and Orkla Group's chemical area. Mr Stenstadvold has been Chairman of Bærum Municipality and Under Secretary at the Ministry of Government Administration. Mr Stenstadvold has broad experience as Board Member, from among others Storebrand ASA, Oslo Stock Exchange and the Resource Council of Norway. Mr Stenstadvold's term expire at the annual general meeting in 2012. Mr Stenstadvold holds indirectly 19,000 and directly 10,000 shares in the Company.

Grete HogstedGrete Hogstad

was elected Director of Navamedic in March 2009. Ms Hogstadholds a Cand. Pharm. degree from the University of Oslo and a business degree from the Norwegian School of Management. Ms Hogstad is Vice Precident Marketing and Sales at Photocure ASA and has held various leading positions in Alpharma and Novo Nordisk Phrama, and is a founding member of the Generics Association in Norway. Grete Hogstad’s term expires at the annual general meeting in 2013. Ms. Hogstad holds no shares in the Company. 

Masha StrømmeMasha Strømme

was elected Director of Navamedic in March 2008. Ms Strømme holds a Ph.D in genetic and neuroscience from Oxford University in UK and has studied at McGill University in Canada. Ms Strømme has experience from investment banking with focus on Life Science from Morgan Stanley and Altium Capitals in London. Masha Strømme's term expires at the annual general meeting in 2012. Ms Strømme holds indirectly 25,000 shares in the Company. 

Svein Erik NicolaysenSvein Erik Nicolaysen

was elected Director of Navamedic in August 2009. Mr Nicolaysen currently holds the position as CEO of the investment company Intersys Norge AS, a part of the group that is the largest shareholders in Navamedic ASA. He is an authorised accountant with accounting practice from Arthur Andersen and Vesterålen-Revisjon AS. From 1998 through 2008, Mr. Nicolaysen was the CEO of the company Vesterålen Naturprodukter AS and Nordic Sales Group AS, companies specialising in direct sales and marketing of health care products such as Omega 3 concentrates.  After these companies were sold to Ferrosan AS (DK), Mr Nicolaysen was a member of the Management Board in Ferrosan AS until the end of 2008. Mr Nicolaysens term expire at the annual general meeting in 2013. Mr Nicolaysen holds 35.000 shares in the Company.